FREMONT, Calif.--(BUSINESS WIRE)--Cordis Corporation announced today three-year health related Quality of Life (QoL) data from the STROLL clinical trial that were presented during a Late-Breaking Clinical Trials session at the Vascular Interventional Advances (VIVA) 2013 Annual Meeting in Las Vegas. Results from the Quality of Life analysis showed that patients with peripheral artery disease (PAD) in the superficial femoral artery (SFA) treated with the S.M.A.R.T.® Vascular Stent Systems (S.M.A.R.T.® Stent) experienced clinically meaningful improvements in Quality of Life, including reduced pain in the affected leg(s), improved social function and increased walking distance, that were maintained over the three year study follow-up period.
Help employers find you! Check out all the jobs and post your resume.
